Table 2.

RNA modification inhibitors as therapeutic targets

RNA modification	target	inhibitor	function	cancer type	references
m6A	FTO	rhein	anti-multidrug resistance	acute myeloid leukemia	[144]
		MO-I-500	inhibition of cell growth	breast cancer	[145]
		R-2HG	inhibition of cell growth	leukemia and glioma	[146]
		meclofenamic acid	restoration of gefinitib sensitivity	non-small cell lung cancer	[147]
		FB23/FB23-2	promotion of differentiation	acute myeloid leukemia	[148]
		CS1/CS2	inhibition of cell growth and immune evasion	acute myeloid leukemia	[93]
		Dac51	promotion of T cell response and response to anti-PD-1 therapy	melanoma	[149]
		18,097	inhibition of cell growth and lung colonization	breast cancer	[150]
		FTO-43	inhibition of cell growth	glioblastoma, acute myeloid leukemia, and gastric cancer	[151]
		C6	inhibition of cell growth	esophageal cancer	[152]
	ALKBH5	ALK-04	inhibition of the infiltration of Treg cells and MDSCs, enhancement of response to anti-PD-1 therapy	melanoma	[78]
	METTL3	STM2457	inhibition of cell growth	acute myeloid leukemia	[153]
		UZH1a	inhibition of cell growth	acute myeloid leukemia	[154]
	YTHDF1	engineered small extracellular vesicles	promotion of IFN-γresponse, MHC I expression	gastric cancer	[155]
	IGF2BP1	small-molecule cucurbitacin B (CuB)	CD4+, CD8 + T cells, CD56 + NK cells, and F4/80 + macrophage infiltration	hepatocellular carcinoma	[117]
m1A	TRMT6 and TRMT61A	Thiram	inhibition of cell growth	hepatocellular carcinoma	[156]
Ψ	PUS7	NSC107512	suppression of tumorigenesis	glioblastoma	[62]
	DKC1	pyrazofurin	inhibition of cell growth	colorectal cancer	[157]

m6A: N6-methyladenosine; FTO: fat mass and obesity-associated protein; ALKBH5: AlkB homolog 5; MDSC: myeloid-derived suppressor cells; METTL3: methyltransferase-like 3; YTHDF1: YTH domain family; IGF2BP1: insulin-like growth factor 2 mRNA-binding protein; TRMT6: tRNA methyltransferase; PUS7: pseudouridine synthase 7